Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Melanoma treatment evolved significantly in 2011 with the introduction of anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitors and BRAF-targeted therapies.
• These advancements have markedly improved overall survival (OS) for patients with advanced melanoma.
• Further progress hinges on understanding the tumor microenvironment (TME) and immune evasion mechanisms.

Purpose of the Study:

• To summarize key findings and discussions from the Melanoma Bridge meeting (December 2019).
• To highlight recent advancements in melanoma research, including novel therapies and biomarkers.
• To explore strategies for overcoming treatment resistance and enhancing immune responses.

Main Methods:

• Review of recent findings in melanoma research presented at the Melanoma Bridge meeting.
• Synthesis of information on tumor microenvironment, immune response, and resistance mechanisms.
• Analysis of emerging combination therapies and biomarker research.

Main Results:

• New immune and targeted therapies have further improved outcomes for advanced melanoma patients.
• Combination modalities (chemotherapy, radiotherapy, electrochemotherapy, surgery) are under investigation.
• Biomarkers are increasingly recognized for predicting therapeutic response.
• Novel strategies are being developed to overcome resistance and potentiate immune responses.

Conclusions:

• The melanoma treatment landscape continues to evolve rapidly with novel immunotherapies and targeted agents.
• Combination strategies, biomarker identification, and understanding resistance mechanisms are crucial for future progress.
• Neoadjuvant and adjuvant therapy roles are critical areas of ongoing research in melanoma management.